Cynata Therapeutics Ltd

51S

Company Profile

  • Business description

    Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

  • Contact

    100 Cubitt Street
    Level 3
    CremorneVIC3121
    AUS

    T: +61 370676940

    https://www.cynata.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    2

Stocks News & Analysis

video

Do you qualify as 'rich'?

Morningstar's Sim Mody speaks with Mark LaMonica about the varying definitions of rich. 
stocks

Solid sales from ASX healthcare leader

Solid device sales with shares moderately undervalued.
stocks

Megatrend Investing: ASX players to capitalise on the clean energy transition

Find out how you can benefit from global megatrends.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,694.6061.200.71%
CAC 407,906.4051.480.66%
DAX 4021,505.7077.460.36%
Dow JONES (US)44,556.04134.130.30%
FTSE 1008,570.7712.79-0.15%
HKSE20,659.34130.62-0.63%
NASDAQ19,654.02262.061.35%
Nikkei 22538,746.4451.93-0.13%
NZX 50 Index12,828.5576.49-0.59%
S&P 5006,037.8843.310.72%
S&P/ASX 2008,427.0053.000.63%
SSE Composite Index3,238.8511.75-0.36%

Market Movers